NICE has assessed the MammaPrint, Oncotype DX, IHC4 and Mammostrat to help the NHS decide whether to use these products.
MammaPrint, Oncotype DX, IHC4 and Mammostrat are tests for certain genes or proteins found in breast cancer tumours. Testing for the levels of these may give healthcare professionals an indication of how a tumour might develop, and therefore help in treatment planning.
NICE has said that Oncotype DX is recommended to help make decisions about chemotherapy after surgery in some people with oestrogen receptor positive (ER+), lymph node negative (LN−) and human epidermal growth factor receptor 2 negative (HER2−) early breast cancer. Your healthcare professional should discuss with you whether this might be right for you.
NICE has said that MammaPrint, IHC4 and Mammostrat should only be used in research. This is because it’s not certain how much benefit they can provide.
This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.